Decorin prevents retinal pigment epithelial barrier breakdown under diabetic conditions by suppressing P38MAPK activation

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 5, 2015, Pages 2971-2979

  Wang, Shuai ^a   Du, Shanshan ^a   Wu, Qiang ^a,b   Hu, Jianyan ^a   Li, Tingting ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b Shanghai Clinical Center for Diabetes Mellitus ^*  (China)

Author keywords

Blood retina barrier; Decorin; Diabetic macular edema; Retinal pigment epithelium

Indexed keywords

CLAUDIN 1; DECORIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE P38; OCCLUDIN; PROTEIN ZO1; SMALL INTERFERING RNA; TIGHT JUNCTION PROTEIN; COBALT; COBALT CHLORIDE; DEXTRAN; FLUORESCEIN ISOTHIOCYANATE;

ARTICLE; BLOOD RETINA BARRIER; CELL DISRUPTION; CELL MEMBRANE PERMEABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DOWN REGULATION; ELECTRIC RESISTANCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANOXIA; CELL CULTURE; CYTOLOGY; DIABETIC RETINOPATHY; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; IMPEDANCE; METABOLISM;

ANOXIA; BLOOD-RETINAL BARRIER; BLOTTING, WESTERN; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; COBALT; DECORIN; DEXTRANS; DIABETIC RETINOPATHY; ELECTRIC IMPEDANCE; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT ANTIBODY TECHNIQUE; GLUCOSE; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RETINAL PIGMENT EPITHELIUM; RNA, SMALL INTERFERING; TIGHT JUNCTION PROTEINS;

EID: 84939832213     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-15874     Document Type: Article

References (54)

1. Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol. 2010;88:279–291.
2. Lightman S, Towler HM. Diabetic retinopathy. Clin Cornerstone. 2003;5:12–21.
3. Joussen AM, Smyth N, Niessen C. Pathophysiology of diabetic macular edema. Dev Ophthalmol. 2007;39:1–12.
4. Simó R, Villarroel M, Corraliza L, Hernández C, Garcia-Ramírez M. The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier—implications for the pathogenesis of diabetic retinopathy. J Biomed Biotechnol. 2010;2010:190-724.
5. Campbell M, Nguyen AT, Kiang AS, et al. An experimental platform for systemic drug delivery to the retina. Proc Natl Acad Sci U S A. 2009;106:17817–17822.
6. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19–48.
7. Fan Y, Liu K, Wang Q, Ruan Y, Ye W, Zhang Y. Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats. Exp Eye Res. 2014;127:104–116.
8. Suarez S, McCollum GW, Bretz CA, Yang R, Capozzi ME, Penn JS. Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-b/d. Invest Ophthalmol Vis Sci. 2014;55:8232–8240.
9. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev. 2005;85:845–881.
10. Willermain F, Libert S, Motulsky E, et al. Origins and consequences of hyperosmolar stress in retinal pigmented epithelial cells. Front Physiol. 2014;5:199.
11. Vinores SA, Gadegbeku C, Campochiaro PA, Green WR. Immunohistochemical localization of blood-retinal barrier breakdown in human diabetics. Am J Pathol. 1989;134:231–235.
12. Aizu Y, Oyanagi K, Hu J, Nakagawa H. Degeneration of retinal neuronal processes and pigment epithelium in the early stage of the streptozotocin-diabetic rats. Neuropathology. 2002;22: 161–170.
13. Decanini A, Karunadharma PR, Nordgaard CL, Feng X, Olsen TW, Ferrington DA. Human retinal pigment epithelium proteome changes in early diabetes. Diabetologia. 2008;51: 1051–1061.
14. Weinberger D, Fink-Cohen S, Gaton DD, Priel E, Yassur Y. Nonretinovascular leakage in diabetic maculopathy. Br J Ophthalmol. 1995;79:728–731.
15. Xu HZ, Le YZ. Significance of outer blood-retina barrier breakdown in diabetes and ischemia. Invest Ophthalmol Vis Sci. 2011;52:2160–2164.
16. Xu HZ, Song Z, Fu S, Zhu M, Le YZ. RPE barrier breakdown in diabetic retinopathy: seeing is believing. J Ocul Biol Dis Infor. 2011;4:83–92.
17. Fan H, Sulochana KN, Chong YS, Ge R. Decorin derived antiangiogenic peptide LRR5 inhibits endothelial cell migration by interfering with VEGF-stimulated NO release. Int J Biochem Cell Biol. 2008;40:2120–2128.
18. Lala N, Girish GV, Cloutier-Bosworth A, Lala PK. Mechanisms in decorin regulation of vascular endothelial growth factorinduced human trophoblast migration and acquisition of endothelial phenotype. Biol Reprod. 2012;87:59.
19. Du S, Wang S, Wu Q, Hu J, Li T. Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1a and VEGF expression in cocultured retinal pigment epithelial cells. Exp Eye Res. 2013;116:151–160.
20. Santra M, Reed CC, Iozzo RV. Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope. J Biol Chem. 2002;277:35671–35681.
21. Ahmed Z, Bansal D, Tizzard K, et al. Decorin blocks scarring and cystic cavitation in acute and induces scar dissolution in chronic spinal cord wounds. Neurobiol Dis. 2014;64:163–176.
22. Frey H, Schroeder N, Manon-Jensen T, Iozzo RV, Schaefer L. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J. 2013;280:2165–2179.
23. Khan GA, Girish GV, Lala N, Di Guglielmo GM, Lala PK. Decorin is a novel VEGFR-2-binding antagonist for the human extravillous trophoblast. Mol Endocrinol. 2011;25:1431–1443.
24. Taniguchi K, Xia L, Goldberg HJ, et al. Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. Diabetes. 2013;62:3874–3886.
25. Lee SJ, Noh KT, Kang TH, et al. The Mycobacterium avium subsp. Paratuberculosis protein MAP1305 modulates dendritic cell-mediated T cell proliferation through Toll-like receptor-4. BMB Rep. 2014;47:115–120.
26. Yan W, Wang P, Zhao CX, Tang J, Xiao X, Wang DW. Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/Smad and p38 mitogen-activated protein kinase signaling pathways. Hum Gene Ther. 2009;20:1190–1200.
27. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81:807–869.
28. Miranda S, González-Rodríguez Á, García-Ramírez M, et al. Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. J Cell Physiol. 2012;227:2352–2362.
29. Carrozzino F, Pugnale P, Féraille E, Montesano R. Inhibition of basal p38 or JNK activity enhances epithelial barrier function through differential modulation of claudin expression. Am J Physiol Cell Physiol. 2009;297:C775–C787.
30. Du Y, Tang J, Li G, et al. Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function. Invest Ophthalmol Vis Sci. 2010;51:2158–2164.
31. Mannermaa E, Reinisalo M, Ranta VP, et al. Filter-cultured ARPE-19 cells as outer blood-retinal barrier model. Eur J Pharm Sci. 2010;40:289–296.
32. Villarroel M, García-Ramírez M, Corraliza L, Hernández C, Simó R. Effects of high glucose concentration on the barrier function and the expression of tight junction proteins in human retinal pigment epithelial cells. Exp Eye Res. 2009;89: 913–920.
33. Trudeau K, Roy S, Guo W, et al. Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability. Invest Ophthalmol Vis Sci. 2011;52:6348–6354.
34. Villarroel M, Garcia-Ramírez M, Corraliza L, Hernández C, Simó R. Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1b by suppressing AMPactivated protein kinase (AMPK) activation. Diabetologia. 2011;54:1543–1553.
35. Garcia-Ramírez M, Villarroel M, Corraliza L, Hernández C, Simó R. Measuring permeability in human retinal epithelial cells (ARPE-19): implications for the study of diabetic retinopathy. Methods Mol Biol. 2011;763:179–194.
36. Sonoda S, Spee C, Barron E, Ryan SJ, Kannan R, Hinton DR. A protocol for the culture and differentiation of highly polarized human retinal pigment epithelial cells. Nat Protoc. 2009;4: 662–673.
37. Harhaj NS, Antonetti DA. Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol. 2004;36:1206–1237.
38. Tian LL, Ren B, Gao XW, et al. Inhibition of retinopathy of prematurity in rat by intravitreal injection of sorafenib. Int J Ophthalmol. 2014;7:198–204.
39. Kernt M, Thiele S, Liegl RG, et al. Axitinib modulates hypoxiainduced blood-retina barrier permeability and expression of growth factors. Growth Factors. 2012;30:49–61.
40. Kernt M, Staehler M, Stief C, Kampik A, Neubauer AS. Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. Acta Ophthalmol. 2008;86:456–458.
41. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med. 2011;15:1013–1031.
42. Yu DY, Cringle SJ. Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease. Prog Retin Eye Res. 2001;20: 175–208.
43. Busik JV, Mohr S, Grant MB. Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. Diabetes. 2008;57:1952–1965.
44. Shiba T, Takahashi M, Hori Y, Saishin Y, Sato Y, Maeno T. Relationship between sleep-disordered breathing and iris and/or angle neovascularization in proliferative diabetic retinopathy cases. Am J Ophthalmol. 2011;151:604–609.
45. Garcia-Ramírez M, Hernández C, Ruiz-Meana M, et al. Erythropoietin protects retinal pigment epithelial cells against the increase of permeability induced by diabetic conditions: essential role of JAK2/ PI3K signaling. Cell Signal. 2011;23: 1596–1602.
46. Villarroel M, García-Ramírez M, Corraliza L, Hernández C, Simó R. High glucose concentration leads to differential expression of tight junction proteins in human retinal pigment epithelial cells. Endocrinol Nutr. 2009;56:53–58.
47. González-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol. 2003;81:1–44.
48. Shen L. Tight junctions on the move: molecular mechanisms for epithelial barrier regulation. Ann N YAcad Sci. 2012;1258: 9–18.
49. Ferrini MG, Moon J, Rivera S, Rajfer J, Gonzalez-Cadavid NF. Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-b1 therapies in inducible nitric oxide synthase-deficient mice. BJU Int. 2012;109:586–593.
50. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429:403–417.
51. Chen XL, Zhang XD, Li YY, Chen XM, Tang DR, Ran RJ. Involvement of HMGB1 mediated signalling pathway in diabetic retinopathy: evidence from type 2 diabetic rats and ARPE-19 cells under diabetic condition. Br J Ophthalmol. 2013;97:1598–1603.
52. Li X, Cai Y, Wang YS, et al. Hyperglycaemia exacerbates choroidal neovascularisation in mice via the oxidative stressinduced activation of STAT3 signalling in RPE cells. PLoS One. 2012;7:e47600.
53. Klettner A, Westhues D, Lassen J, Bartsch S, Roider J. Regulation of constitutive vascular endothelial growth factor secretion in retinal pigment epithelium/choroid organ cultures: p38, nuclear factor jB, and the vascular endothelial growth factor receptor-2/phosphatidylinositol 3 kinase pathway. Mol Vis. 2013;19:281–291.
54. Zhang C, Wang H, Nie J, Wang F. Protective factors in diabetic retinopathy: focus on blood-retinal barrier. Discov Med. 2014; 18:105–112.